Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Janux Therapeutics, Inc. (JANX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.41-0.65 (-5.88%)
At close: 04:00PM EDT
10.41 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement

Janux Therapeutics, Inc.

11099 North Torrey Pines Road
Suite 290
La Jolla, CA 92037
United States
858-750-4700
https://www.januxrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Dr. David Alan CampbellPres, CEO & Director585.81kN/A1960
Mr. Tighe M. Reardon C.F.A., CPA, CPAActing Chief Financial OfficerN/AN/A1976
Mr. Tommy Diraimondo Ph.D.Director of ResearchN/AN/AN/A
Dr. Shahram Salek-Ardakani Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Andy Hollman MeyerChief Bus. OfficerN/AN/A1984
Mr. Charles M. WinterSr. VP of Chemistry, Manufacturing & ControlsN/AN/AN/A
Dr. Wayne Godfrey M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Corporate Governance

Janux Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement